Stock SLGL SOL-GEL TECHNOLOGIES LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Company Sol-Gel Technologies Ltd.

Equities

SLGL

IL0011417206

Biotechnology & Medical Research

Delayed Nasdaq
Other stock markets
 12:07:45 2024-04-26 pm EDT 		5-day change 1st Jan Change
0.8899 USD +3.36% Intraday chart for Sol-Gel Technologies Ltd. -5.33% -19.47%
Mar. 13 Sol-Gel Technologies Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Feb. 29 Sol-Gel Technologies Ltd. Elects Yuval Yanai as External Director CI

Business Summary

Sol-Gel Technologies Ltd is a clinical-stage dermatology company. The Company is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The Company is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.

Number of employees: 36

Sales per Business

USD in Million2022Weight2023Weight Delta
Topical Dermatological Drug
100.0 %
4 100.0 % 2 100.0 % -59.98%

Sales per region

USD in Million2022Weight2023Weight Delta
Israel
100.0 %
4 100.0 % 2 100.0 % -59.98%

Managers

Managers TitleAgeSince
Alon Seri-Levy FOU
 Founder 62 97-10-27
Gilad Mamlok DFI
 Director of Finance/CFO 56 17-01-31
Itzik Yosef COO
 Chief Operating Officer 48 09-12-31
Ofra Levy-Hacham CTO
 Chief Tech/Sci/R&D Officer 59 10-12-31
Ofer Toledano CTO
 Chief Tech/Sci/R&D Officer 60 03-12-31
Michael Glezin PRN
 Corporate Officer/Principal - 22-10-02
Tami Fishman Jutkowitz LAW
 General Counsel 48 23-02-28

Members of the board

Members of the board TitleAgeSince
Sharon Kochan BRD
 Director/Board Member 55 23-07-25
Jonathan Siegel BRD
 Director/Board Member 50 18-09-12
Moshe Arkin CHM
 Chairman 69 13-12-31
Alon Seri-Levy FOU
 Founder 62 97-10-27
Ran Gottfried BRD
 Director/Board Member 79 17-12-31
Hanna Lerman BRD
 Director/Board Member 51 17-12-31
Itai Arkin BRD
 Director/Board Member 35 17-12-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 27,857,620 9,703,056 ( 34.83 %) 0 34.83 %

Shareholders

NameEquities%Valuation
Moshe Arkin
65.17 %
18,154,564 65.17 % 18 M $
THE PHOENIX HOLDINGS LTD.
9.243 %
2,574,922 9.243 % 3 M $
Armistice Capital LLC
7.664 %
2,135,000 7.664 % 2 M $
MIGDAL INSURANCE AND FINANCIAL HOLDINGS LTD.
4.407 %
1,227,548 4.407 % 1 M $
HAREL INSURANCE INVESTMENTS & FINANCIAL SERVICES LTD
3.304 %
920,333 3.304 % 901 926 $
Kingdon Capital Management LLC
2.423 %
674,923 2.423 % 661 425 $
THE PHOENIX HOLDINGS LTD.
1.034 %
288,045 1.034 % 282 284 $
Yelin Lapidot Holdings Management Ltd.
0.8227 %
229,178 0.8227 % 224 594 $
Raymond James Financial Services, Inc.
0.1764 %
49,130 0.1764 % 48 147 $
Raymond James & Associates, Inc.
0.1112 %
30,977 0.1112 % 30 357 $

Company contact information

Sol-Gel Technologies Ltd.

Weizmann Science Park 7 Golda Meir Street

74036, Ness Ziona

+972 8 931 3433

http://www.sol-gel.com
address Sol-Gel Technologies Ltd.(SLGL)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Ratings for Sol-Gel Technologies Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.861 USD
Average target price
8 USD
Spread / Average Target
+829.15%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
SOL-GEL TECHNOLOGIES LTD. Stock Sol-Gel Technologies Ltd.
-19.47% 23.99M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.83% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.46% 95.71B
ARGENX SE Stock argenx SE
+1.69% 22.02B
BIONTECH SE Stock BioNTech SE
-17.30% 20.9B
GENMAB A/S Stock Genmab A/S
-9.30% 17.85B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.21B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.84% 15.52B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.92% 13.86B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+35.57% 12.04B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. SLGL Stock
  4. Company Sol-Gel Technologies Ltd.